Active Biotech AB Interim report January - March 2014

        Print
| Source: Active Biotech AB
Laquinimod
  * On January 24, the laquinimod (Nerventra®) market application received a
    negative opinion by the Committee for Medicinal Products for Human Use
    (CHMP) of the European Medicines Agency (EMA).

  * Teva has requested a re-examination of the CHMP's opinion.

  * In February 2014, Teva decided not to proceed with the randomization stage
    of the planned LIBRETTO trial for the treatment of relapsing remitting
    multiple sclerosis (RRMS) since the current design is no longer aligned with
    the regulatory strategy.
  * The ongoing US pivotal clinical study CONCERTO is continuing according to
    plan. The results are expected in 2016.

Tasquinimod
  * In February 2014, Ipsen launched a randomized, double-blind, placebo-
    controlled Phase III study of tasquinimod in chemo-naive CRPC patients in
    Asia.

  * The Phase III 10TASQ10 study is proceeding as planned; the primary analysis
    of progression-free survival (PFS) and overall survival (OS) is expected in
    2014.

Paquinimod (57-57)
  * In January 2014, paquinimod, for the treatment of systemic sclerosis, was
    granted orphan drug status by the US Food and Drug Administration (FDA).
    Orphan drug status in the US provides advantages such as market exclusivity
    for a period of seven years upon approval.

Financial summary
  * Net sales 2.1 (2.4) MSEK
  * Operating loss -59.2 (-77.0) MSEK
  * Loss for the period -60.2 (-78.0) MSEK
  * Loss per share -0.80 (-1.10) SEK


For further information, please contact:


 Tomas Leanderson,       Active Biotech AB
 President and CEO       (Corp. Reg. No. 556223-9227)
 Tel: +46 (0)46 19 20 95 Box 724, SE-220 07 Lund
                         Tel: +46 (0)46 19 20 00
 Hans Kolam, CFO         Fax: +46 (0)46 19 11 00
 Tel: +46 (0)46 19 20 44 The report is also available at
                         www.activebiotech.com
                         

[HUG#1779362]